---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-112866"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:37:54.254424+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organon Q3 revenue $1.582B (+4% YoY); narrows FY revenue guidance upward to $6.375-6.425B

## Summary
- GAAP diluted EPS $1.38; non-GAAP adjusted diluted EPS $0.87 (includes $0.16 IPR&D charge).
- Women's Health +5% as-reported; Nexplanon grew 11% ex-FX; fertility +14% ex-FX.
- Biosimilars +16% as-reported; Hadlima launch drove uptake; Renflexis +4% ex-FX.
- FY2024 revenue midpoint raised $50M to $6.375-6.425B; Adj. EBITDA margin guide revised to 30-31%.
- Established Brands +2% as-reported; flat ex-FX growth expected for full year.

## SEC filing metadata
- accession: 0001104659-24-112866
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465924112866/0001104659-24-112866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465924112866/tm2427187d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-112866
- JSON: https://secwatch.observer/filing/0001104659-24-112866.json
- Plain text: https://secwatch.observer/filing/0001104659-24-112866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.